Asparaginase

ERYTECH Sells U.S. Manufacturing Facility and Enters Long-Term Supply Agreement with Catalent

Retrieved on: 
Monday, April 25, 2022
Nasdaq, Catalent, Sale, Cooley LLP, Patient, European Medicines Agency, Technology, FDA, Acquisition, 150, CAC All-Tradable, CAC Mid 60, DNA, CDMO, Food, TILS, Employment, IST, Company, Asparaginase, Euronext Paris, Partnership, Acute lymphoblastic leukemia, LLP, Medicine, Asparagine, CAC, Pancreatic cancer, APA, ALL, GMP, Growth, ISIN, NKS, Industry, BLA, Euronext, Therapy, Organic acid, Cancer, Survival, Microsoft, Potyvirus, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, AAV, Metabolism, TCR, Pharmaceutical industry, Security (finance), Fine chemical, Princeton University

Under the terms of an asset purchase agreement between ERYTECH and Catalent (the APA), Catalent agreed to acquire ERYTECHs state-of-the-art commercial-scale cell therapy manufacturing facility in Princeton, New Jersey, for a total consideration of $44.5 million.

Key Points: 
  • Under the terms of an asset purchase agreement between ERYTECH and Catalent (the APA), Catalent agreed to acquire ERYTECHs state-of-the-art commercial-scale cell therapy manufacturing facility in Princeton, New Jersey, for a total consideration of $44.5 million.
  • ERYTECHs Princeton facility is a 30,900 sqft cutting edge manufacturing facility, designed with the flexibility to expand to support various cell therapy production requirements and capacities.
  • ERYTECH will retain its manufacturing site in Lyon, France and its expertise and capabilities in manufacturing process science to continue innovating in cell therapy manufacturing.
  • The parties will also enter into a long-term supply agreement for the manufacturing and supply of the lead product candidate eryaspase (GRASPA) by Catalent to ERYTECH.

ERYTECH Announces Publication of Positive Results from Eryaspase Phase 2 Trial in Hypersensitive ALL in the British Journal of Haematology

Retrieved on: 
Wednesday, April 6, 2022
IST, CAC All-Tradable, CAC, Asparaginase, European Medicines Agency, Medicine, ISIN, Technology, Asparagine, Nasdaq, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, GMP, Pancreatic cancer, 150, Wiley, CAC Mid 60, Hypersensitivity, Metabolism, Allergy, Principal investigator, Organic acid, Growth, Survival, Nordic Society for Middle Eastern Studies, ALL, FDA, Patient, Company, British Journal of Haematology, Bone marrow, Paper, Associate, Cancer, Food, Acute lymphoblastic leukemia, Safety, Aarhus University Hospital, PHASE 2, Blood, Pharmaceutical industry, Medical imaging, Red blood cell, Euronext

The Phase 2 NOR-GRASPALL-2016 trial evaluated the safety and pharmacological profile of eryaspase in ALL patients who had previously experienced hypersensitivity reactions to pegylated asparaginase therapy.

Key Points: 
  • The Phase 2 NOR-GRASPALL-2016 trial evaluated the safety and pharmacological profile of eryaspase in ALL patients who had previously experienced hypersensitivity reactions to pegylated asparaginase therapy.
  • Eryaspase demonstrated sustained asparaginase enzyme activity above the threshold of >100 U/L at trough levels 14 days after first infusion in 92.5% of patients.
  • The Principal Investigator, Dr. Birgitte Klug Albertsen, Associate Professor at Aarhus University Hospital, Denmark, commented, "I am grateful that the editors of the British Journal of Haematology selected our study for publication.
  • ERYTECH is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes.

ERYTECH to Present Novel Vesiculation Approach at the 24th Meeting of the European Red Cell Society

Retrieved on: 
Monday, April 4, 2022
IST, Company, CAC All-Tradable, Metabolism, Red blood cell, Carrier, CAC, Organic acid, Growth, ERCS, Asparaginase, European Medicines Agency, TM, Survival, Time zone, Program, Cancer, Medicine, CEO, Food, ISIN, Acute lymphoblastic leukemia, ALL, Seminal vesicles, 150, Technology, Asparagine, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Nasdaq, GMP, FDA, RBC, CAC Mid 60, Pancreatic cancer, Patient, Fine chemical, Vaccine, Pharmaceutical industry, Euronext

Oral presentation: Evaluation of production methods, characterization and biological activity of RBC-derived extracellular vesicles (RBCEVs) containing active molecules.

Key Points: 
  • Oral presentation: Evaluation of production methods, characterization and biological activity of RBC-derived extracellular vesicles (RBCEVs) containing active molecules.
  • Vesiculation of RBCs that have already been loaded with active therapeutic compounds utilizing the ERYCAPS process, entails the potential of producing cargo-loaded RBC-derived extracellular vesicles for the development of novel therapeutic approaches.
  • ERYTECH is a clinical-stage biopharmaceutical company developing innovative red blood cell-based therapeutics for severe forms of cancer and orphan diseases.
  • ERYTECH is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes.

ERYTECH to Participate in the Upcoming April Investor Conferences

Retrieved on: 
Monday, March 28, 2022
IST, Company, CAC All-Tradable, Metabolism, Euronext, CAC, Organic acid, Growth, Asparaginase, European Medicines Agency, Survival, Cancer, Medicine, Food, ISIN, Acute lymphoblastic leukemia, ALL, 150, Technology, Asparagine, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, GMP, FDA, Nasdaq, CAC Mid 60, Pancreatic cancer, Patient, Pharmaceutical industry

ERYTECH is a clinical-stage biopharmaceutical company developing innovative red blood cell-based therapeutics for severe forms of cancer and orphan diseases.

Key Points: 
  • ERYTECH is a clinical-stage biopharmaceutical company developing innovative red blood cell-based therapeutics for severe forms of cancer and orphan diseases.
  • Leveraging its proprietary ERYCAPS platform, which uses a novel technology to encapsulate drug substances inside red blood cells, ERYTECH is developing a pipeline of product candidates for patients with high unmet medical needs.
  • The FDA and the European Medicines Agency have granted eryaspase orphan drug status for the treatment of pancreatic cancer and ALL.
  • ERYTECH is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes.

DGAP-News: Kizoo Portfolio Company Revel Pharmaceuticals Announces $8.4M Seed to Develop Repairing-Based Approaches to Reversing Aging

Retrieved on: 
Thursday, March 17, 2022
Time, Asparaginase, CA, Collagen, Ageing, Technology, Kidney, Death, Mentorship, Health, Patient, Enzyme, Revel, Conference, Therapy, Disease, Cardiovascular disease, Risk, VC, David Evans (Yale professor), Diabetes, Human, Cystic fibrosis, Investment, Stroke, Kidney disease, Research, Cancer, Osteoarthritis, Inflammation, CEO, Yale University, Degenerative disease, Deoxyribonuclease, Longevity, Engineering, Metabolism, Glycogen storage disease, Imiglucerase, Pharmaceutical industry, Seed, KIZOO, Revel Pharmaceuticals, KIZOO, REVEL PHARMACEUTICALS

Led by Kizoo Technology Capital, the Seed round will be used to advance Revel Pharmaceuticals' enzyme therapy pipeline towards the clinic.

Key Points: 
  • Led by Kizoo Technology Capital, the Seed round will be used to advance Revel Pharmaceuticals' enzyme therapy pipeline towards the clinic.
  • San Francisco, CA, U.S., March 17, 2022 - Revel Pharmaceuticals, a longevity therapeutics company developing enzymes to repair damage from aging, announced today that it has raised $8.4M in Seed financing.
  • Revel Pharmaceuticals is reimagining how enzymes can be used as therapeutics by developing repair-based approaches to aging and disease.
  • "Revel is leading innovation in repair-based approaches to aging", says Patrick Burgermeister, Partner at Kizoo Technology Capital and board member of Revel Pharmaceuticals.

Kizoo Portfolio Company Revel Pharmaceuticals Announces $8.4M Seed to Develop Repairing-Based Approaches to Reversing Aging

Retrieved on: 
Thursday, March 17, 2022
Time, Asparaginase, CA, Ageing, Technology, GLOBE, Kidney, Death, Mentorship, Health, Enzyme, Revel, Conference, Therapy, Disease, Cardiovascular disease, Risk, VC, David Evans (Yale professor), Diabetes, Human, Cystic fibrosis, Investment, Stroke, Kidney disease, Research, Cancer, Osteoarthritis, Inflammation, CEO, Yale University, Degenerative disease, Deoxyribonuclease, Longevity, Engineering, SAN, Metabolism, Glycogen storage disease, Imiglucerase, Pharmaceutical industry

SAN FRANCISCO, March 17, 2022 (GLOBE NEWSWIRE) -- Revel Pharmaceuticals, a longevity therapeutics company developing enzymes to repair damage from aging, announced today that it has raised $8.4M in Seed financing.

Key Points: 
  • SAN FRANCISCO, March 17, 2022 (GLOBE NEWSWIRE) -- Revel Pharmaceuticals, a longevity therapeutics company developing enzymes to repair damage from aging, announced today that it has raised $8.4M in Seed financing.
  • Revel Pharmaceuticals is reimagining how enzymes can be used as therapeutics by developing repair-based approaches to aging and disease.
  • Revel is leading innovation in repair-based approaches to aging, says Patrick Burgermeister, Partner at Kizoo Technology Capital and board member of Revel Pharmaceuticals.
  • By addressing one of the hallmarks of aging, Revel is strategically positioned to develop therapeutics for multiple diseases of aging including osteoarthritis, kidney disease, cardiovascular disease, skin aging, and complications of diabetes.

ERYTECH Expands Patent Portfolio for the Treatment of Rare Metabolic Diseases

Retrieved on: 
Tuesday, February 8, 2022
Hyperhomocysteinemia, CAC Mid 60, Enzyme, IST, ISIN, European Medicines Agency, Growth, Patent, Lists of diseases, Septic shock, Metabolic disorder, Organic acid, Medicine, CAC All-Tradable, 150, Asparagine, A1, Company, Cancer, GMP, ALL, Arginine, FDA, Technology, Patient, Pancreatic cancer, Euronext Paris, Liver, Survival, Blood, Metabolism, Method, Hypersensitivity, Therapy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Phenylketonuria, ADI, Acute lymphoblastic leukemia, Homocystinuria, Asparaginase, Food, Nasdaq, Euronext, CAC, ERT, Pharmaceutical industry

The claims will also cover methods of treating other indications, including arginine-dependent cancers, septic shock, and angiogenesis-associated diseases.

Key Points: 
  • The claims will also cover methods of treating other indications, including arginine-dependent cancers, septic shock, and angiogenesis-associated diseases.
  • Gil Beyen, Chief Executive Officer of ERYTECH, commented, We are very pleased to expand our patent coverage for our red blood cell platform in rare disease.
  • ERYTECH currently has a patent portfolio of about 310 issued patents and over 45 pending patent applications worldwide covering 16 patent families.
  • ERYTECH is a clinical-stage biopharmaceutical company developing innovative red blood cell-based therapeutics for severe forms of cancer and orphan diseases.

ERYTECH Announces Presentation of Results of Two Clinical Trials of Eryaspase in Pancreatic Cancer at ASCO GI

Retrieved on: 
Monday, January 24, 2022
Medicine, CAC, European Medicines Agency, Cancer, FOLFIRI, Johns Hopkins, Technology, BLA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, ISIN, DLT, 150, MTD, SD, Pancreatic cancer, Metabolism, Nasdaq, Company, CAC Mid 60, Doctor of Philosophy, Asparagine, Department of Oncology, University of Cambridge, ASCO, Food, FDA, Survival, APHP, Asparaginase, Patient, CAC All-Tradable, Organic acid, Growth, Society, Acute lymphoblastic leukemia, Georgetown Lombardi Comprehensive Cancer Center, FOLFIRINOX, Toxicity, CI, Hypersensitivity, Index (publishing), University, PR, Population, ALL, Department, GMP, IST, Respect, HR, Pharmaceutical industry, Irinotecan, Euronext, MD

The novel combination of mFOLFIRINOX plus eryaspase was well tolerated and no dose limiting toxicity (DLT) was observed.

Key Points: 
  • The novel combination of mFOLFIRINOX plus eryaspase was well tolerated and no dose limiting toxicity (DLT) was observed.
  • Pancreatic cancer remains very difficult to treat with few treatment options, but we have been encouraged by the clinical activity observed with eryaspase in both trials.
  • The proof of concept of eryaspase as a cancer metabolism agent was established in different trials in acute lymphoblastic leukemia (ALL) and pancreatic cancer.
  • The FDA and the European Medicines Agency have granted eryaspase orphan drug status for the treatment of pancreatic cancer and ALL.

ERYTECH Announces Presentation of Results of Expanded Access Program in ALL at 2021 ASH Annual Meeting and Acceptance of Two Abstracts at ASCO GI

Retrieved on: 
Monday, December 13, 2021
Escherichia coli, ASN, Authorization, ASCO, Nasdaq, Asparagine, Allergy, Institute, 2021 Essex County Council election, Risk, Hypersensitivity, Patient, Pediatric Hematology and Oncology, Asparaginase, Acute lymphoblastic leukemia, EAP, ASH, ALL, Pancreatic cancer, CA, Hematology, Society, Pharmaceutical industry, Medicine

The EAP results provide additional support for the feasibility of eryaspase (GRASPA) to continue the intended course of treatment of ALL patients who developed hypersensitivities to other asparaginases.

Key Points: 
  • The EAP results provide additional support for the feasibility of eryaspase (GRASPA) to continue the intended course of treatment of ALL patients who developed hypersensitivities to other asparaginases.
  • Two abstracts have been accepted for presentation at the ASCO GI annual conference in January 2022.
  • ERYTECH is a clinical-stage biopharmaceutical company developing innovative red blood cell-based therapeutics for severe forms of cancer and orphan diseases.
  • ERYTECH is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes.

ERYTECH Secures US Patent Directed to Sequential Use of Methioninase & Asparaginase against Solid Tumors

Retrieved on: 
Monday, November 29, 2021
GMP, Tissue, Patient, Asparaginase, Methionine, CAC Mid 60, IST, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, 150, European Medicines Agency, Safety, Half-life, Technology, Company, Neoplasm, Biology, Pancreatic cancer, CAC All-Tradable, Cancer, Nutrient, Inborn errors of metabolism, Therapy, Metabolism, Food, ALL, CAC, Survival, Nasdaq, Lists of diseases, Organic acid, Patent, Acute lymphoblastic leukemia, ISIN, Asparagine, FDA, Immunotherapy, Medicine, Stomach, Method, Enzyme, Growth, Pharmaceutical industry

In total, ERYTECHs IP portfolio now includes 16 global patent families with over 310 patents and 45 applications.

Key Points: 
  • In total, ERYTECHs IP portfolio now includes 16 global patent families with over 310 patents and 45 applications.
  • As disclosed in the patent, ERYTECH scientists determined that certain solid tumors including gastric cancer were unexpectedly sensitized to treatment with asparaginase subsequent to prior treatment with methioninase.
  • ERYTECH currently has a patent portfolio of about 310 issued patents and over 45 pending patent applications worldwide covering 16 patent families.
  • ERYTECH is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes.